Operant Conditioning of Spinal Reflexes Training System--Reflex Operant Down Conditioning
Launched by MEDICAL UNIVERSITY OF SOUTH CAROLINA · Oct 14, 2021
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new training system designed to help individuals with spinal cord injuries (SCI) who experience muscle stiffness or spasticity, particularly in their legs. The goal is to see if this training can effectively change the way certain reflexes work in the body. To participate, individuals must be between the ages of 65 and 74, have a stable spinal cord injury that happened at least a year ago, and be able to walk at least 10 meters, even if they need a walking aid like a cane or a walker.
Participants will take part in the study over approximately six months, with around 45 visits expected during that time. Throughout the study, researchers will monitor medications and overall health to ensure participants are stable and safe. It's an exciting opportunity for those who meet the criteria to potentially improve their mobility and manage their spasticity better through this innovative training approach.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. a clinically stable spinal cord injury (above T11) that occurred at least one year previously
- • 2. the ability to ambulate at least 10 m with or without an assistive device (i.e., walker, crutches, or cane, not parallel bars) within 100 sec (those with 10-meter walking time \>100 sec are excluded because it is unlikely that they are able to participate in and complete our planned locomotion evaluation procedures)
- • 3. clinical signs of spasticity in the plantarflexor muscles at least unilaterally (i.e., hyperreactivity to Achilles tendon tap, and increased muscle tone, score \>1 on Modified Ashworth scale)
- • 4. spastic hyperreflexia reflected in exaggerated H-reflex
- • 5. functionally and medically stable for at least 3 months
- • 6. medical clearance to participate
- • 7. reasonable expectation that current medications (including antispasticity medication such as baclofen, diazepam, and tizanidine) will not change over the conditioning period. Each participant's medication and dosage will be monitored and recorded throughout the study. Once enrolled, the subject will remain enrolled even if medication changes. (Because only neurologically stable subjects will enter this study, medication changes will be unlikely.)
- Exclusion Criteria:
- • 1. motoneuron injury;
- • 2. a cardiac condition (history of myocardial infarct, pacemaker use, etc.)
- • 3. an unstable medical condition
- • 4. a pre-existing or confounding neurological condition (e.g., history of Multiple Sclerosis (MS), Traumatic Brain Injury (TBI), Stroke, Parkinson's disease)
- • 5. a condition that prevents lower extremity mobility testing or weight bearing (e.g. fracture, severe sprain/strain, botox muscular injection) (orthotic knee hyperextension is not excluded; in severe cases of knee hyperextension, the brace can be worn during the study sessions)
- • 6. a cognitive impairment that precludes giving informed consent (e.g., severe intellectual disability)
- • 7. use of a functional electrical stimulation (FES) foot-drop stimulator or an FES bicycle on a daily basis (FES applied to the arm is acceptable)
- • 8. deep vein thrombosis within the past 6 months
- • 9. depression (due to potential interference of anti-depressant medication with the intervention and possible reduced participation reliability)
- • 10. pregnancy (due to expected changes in weight and posture and potentially unstable medical condition).
About Medical University Of South Carolina
The Medical University of South Carolina (MUSC) is a leading academic health center dedicated to advancing medical research and improving patient care through innovative clinical trials. With a strong emphasis on translational medicine, MUSC leverages its extensive resources and expertise to facilitate groundbreaking studies across various medical disciplines. The institution is committed to fostering collaboration among researchers, healthcare professionals, and patients, ensuring that cutting-edge discoveries translate into effective treatments. As a pioneer in health education and research, MUSC plays a vital role in shaping the future of medicine and enhancing health outcomes in the community and beyond.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Charleston, South Carolina, United States
Patients applied
Trial Officials
Aiko Thompson, PhD
Principal Investigator
Medical University of South Carolina
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials